Black Patients Less Likely to Receive Therapy

Article

A study in JAMA, the Journal of the American Medical Association, shows that black patients were 30 percent lee likely to receive specialized heart procedures in comparison to white patients.

A study in JAMA, the Journal of the American Medical Association, shows that black patients were 30 percent lee likely to receive specialized heart procedures in comparison to white patients.

Recent Videos
Alvin Wells, MD, PhD
Harnessing Patient Insights: The Role of PROs in Managing Psoriasis and Psoriatic Arthritis
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Siddharth Patel, MD, MPH | Credit: TIMI Study Group
Kausik Ray, MD, MPhil | Credit: BAIM Institute
Rahul Aggarwal, MD | Credit: LinkedIn
Kenneth Mahaffey, MD | Credit: Stanford University
Sara Diaz Saravia, MD | Credit: X.com
Related Content
Stock image of a woman experiencing chest pain. | Credit: Fotolia

Study Finds Traditional Risk Scores Miss Most Patients at Risk of First Heart Attack

Patrick Campbell
September 9th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
April 17th 2024
Podcast
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University

Aficamten in the Spotlight at ESC Congress, with Ahmad Masri, MD, MS

Patrick Campbell
September 4th 2024
Article
"New Insight with Veeral Sheth, MD" logo | Image Credit: HCPLive

New Insight: Role of Contract Research Organizations in Retina w/ Brad Doerschuk

Connor Iapoce
February 29th 2024
Podcast
Gil Yosipovitch, MD: Next Steps Following FDA Approval of Nemolizumab for Prurigo Nodularis

Gil Yosipovitch, MD: Next Steps Following FDA Approval of Nemolizumab for Prurigo Nodularis

Tim Smith
August 19th 2024
Article
What the FDA Approval of Nemolizumab Means for Prurigo Nodularis, with Gil Yosipovitch, MD

What the FDA Approval of Nemolizumab Means for Prurigo Nodularis, with Gil Yosipovitch, MD

Tim Smith
August 17th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.